INKT
MiNK Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.64
+3.65%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -2.1%
- EBIT
- -21.9%
- EPS
- +17.3%
- Free cash flow
- -55.0%
- Operating cash flow
- -55.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +67.7%
- EPS
- -25.4%
Three-year CAGR
- Revenue
- —
- EBITDA
- -16.5%
- EBIT
- -17.2%
- Net income
- -15.9%
- EPS
- -1.0%
- Free cash flow
- +38.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026